Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of subjects who developed symptomatic UTI (6 months to 1 year) · adults with asymptomatic bacteriuria
The intervention showed no clear difference in number of subjects who developed symptomatic UTI (6 months to 1 year) (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects who developed complications (10 months to 3 years) · adults with asymptomatic bacteriuria
The intervention showed no clear difference in number of subjects who developed complications (10 months to 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Death (6 months to 8 years) · adults with asymptomatic bacteriuria
The intervention showed no clear difference in death (6 months to 8 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects who develop any adverse event (42 days to 10 months) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects who develop any adverse event (42 days to 10… (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects with bacteriological cure (42 days to 4 years) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects with bacteriological cure (42 days to 4 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of pulmonary tuberculosis in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of pulmonary tuberculosis in children with HIV infection ‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention leads to lower episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pneumocystis carinii pneumonia infection in children with cancer ‐ trimethoprim‐sulfamethoxazole prophylaxis only · children with cancers aged 12 years and under
The intervention probably leads to lower incidence of Pneumocystis carinii pneumonia infection in children… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention probably leads to lower mortality in children with HIV infection ‐ co‐trimoxazole… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review